'Arthur Andrew Medical is excited to announce the arrival of our newest formulation in our line of ever-popular enzyme supplements. Although we have been extremely happy with the success of our Devacor formulation, with recent advances in enzyme technology we felt that the product could be improved upon. It is our mission to provide the most advanced, potent, and clinically effective products available. Making formulation changes is often an arduous but necessary task to achieve and maintain that goal. In light of these new developments, we are proud to announce the arrival of Devigest, which will replace Devacor as our premier digestive aid.
The new, more concentrated formula will provide at least as much or more digestive capability than Devacor with smaller, easier-to-swallow capsules and will come in both 90 and 180 capsule bottles. Devigest contains an advanced acid-stable protease blend for enhanced protein digestibility, which includes Dipeptidyl Peptidase, also known as DPP-IV. This specific enzyme is known for its ability to break down gluten and casein, which are both known today as leading sources of digestive distress in complex carbohydrate intolerance and celiac disease sufferers.
Devigest also includes over 400% more lactase per serving than Devacor, which will help those suffering from lactose intolerance enjoy dairy without the gastrointestinal discomfort. In addition, alpha galactosidase (the enzyme contained in the popular supplement Beano®) is now included in the formula to lessen the incidence of intestinal gas and bloating. Devigest will be available through Southwest Nutraceuticals starting in early March, 2011.'
Daniel E. Curtin
Director of Operations
Arthur Andrew Medical